# Early Alzheimer’s Disease: Developing Drugs for Treatment - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/early-alzheimers-disease-developing-drugs-for-treatment/ef0ff9a7-7208-4951-acbb-acb9937f83e7

> FDA guidance document: Early Alzheimer’s Disease: Developing Drugs for Treatment. Issue date: March 12, 2024. Get complete insights and analysis.

---

## Details

- Title: Early Alzheimer’s Disease: Developing Drugs for Treatment
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2024-03-12
- Comment Close Date: 2024-06-10
- Last Changed: 2024-03-12
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2013-D-0077">FDA-2013-D-0077</a>

## Related Documents

- [Safety Labeling Changes—Implementation of Section 505(o)(4) of the FD&C Act: Draft Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/safety-labeling-changesimplementation-of-section-505o4-of-the-fdc-act-draft-guidance-for-industry/2ed7dede-8a3f-4f38-baa2-5eec541a5edb)
- [Measuring Growth and Evaluating Pubertal Development in Pediatric Clinical Trials; Draft Guidance for Industry; Availability](https://www.globalkeysolutions.net/guidances/guidance-document/measuring-growth-and-evaluating-pubertal-development-in-pediatric-clinical-trials-draft-guidance-for-industry-availability/b3766e09-0a47-4099-a69c-f48ac2979eb8)
- [Fabry Disease: Developing Drugs for Treatment Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/fabry-disease-developing-drugs-for-treatment-guidance-for-industry/37d2e0fe-939f-490c-8fec-d2753a0f2f8c)